Spinout Active LTD

Company profile

Entia Ltd

Entia

Entia is making life better for people receiving cancer treatment.

CRN
09283492
Founded
2014
Age
11

Overview

Browse spinouts
Legal name
ENTIA LTD
Region
London
Registered address
6 LLOYD'S AVENUE
LONDON
UNITED KINGDOM
EC3N 3AX
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

6 levels 4 ultimate controllers
1
Company Active LTD
Entia Ltd
CRN 09283492
2
Direct controller Active LTD
3
Intermediate controller Active PLC
BGF Group PLC
CRN 10657226
4
Intermediate controller Active LTD
5
Intermediate controller Active LTD
6
Intermediate controller Active LTD
7
Intermediate controller Active LTD
8
Intermediate controller Active PLC
HSBC Bank PLC
CRN 00014259
9
Intermediate controller Active LTD
10
Intermediate controller Active LTD
11
Intermediate controller Active LTD
12
Ultimate controller Active PLC
HSBC Holdings PLC
CRN 00617987
13
Intermediate controller Active LTD
14
Ultimate controller Active PLC
Natwest Group PLC
CRN SC045551
15
Ultimate controller Active PLC
16
Ultimate controller Active PLC
Barclays PLC
CRN 00048839

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Aug
2027

Accounts due

Accounts Due

Next accounts due date

04 Nov
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Nov
2025

Accounts filed

Accounts

Last accounts made up date

21 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

28 Oct
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0MTEyMDcwNGFkaXF6a2N4

Published 28 Oct 2024 01:51

28 Oct
2014

Incorporated

Inception

Company registered at Companies House

Spinout profile

3 entries

Company description

Entia produces a portable machine for the diagnosis of anaemia.

Entia is a multidisciplinary team spanning design, engineering, quality assurance, business development and innovation.

Project impact

Simplified blood testing

Entia
2014
Entia
2014
ENTIA LTD
2014

Public funding

8 awards
First funded
2015
Funded years
2015, 2017, 2019, 2020
Age at first award
0 years

Projects

2020 Feasibility Studies Lead participant

Continuity of Development for a Home Oncology Management System

1 Jun 2020 to 30 Nov 2020

Awarded
£247,997
Total cost £247,997

no public description

2020 Feasibility Studies Lead participant

Chronic Kidney Disease patient management during Covid-19

1 Jun 2020 to 30 Nov 2020

Awarded
£49,840
Total cost £49,840

Entia in partnership with the NHS has developed a new approach to managing chronic kidney disease. This project seeks to ensure that the solution developed addresses the needs of NHS trusts and renal centres across the UK.

2019 Collaborative R&D Lead participant

Anaemia of Chronic Kidney Disease: Empowering patients by bringing treatment closer to them

1 Oct 2019 to 30 Jun 2021

Awarded
£221,786
Total cost £492,858

"Entia, Hull University Teaching Hospitals NHS Trust and the Yorkshire & Humber Academic Health Science Network are developing a new approach to the management of patients with anaemia of chronic kidney disease. The project encompasses the late stage development of an anaemia management solution that will be co-designed and evaluated with patients and hea...

2019 Collaborative R&D Lead participant

Affinity: Home blood count monitoring for personalised delivery of cancer therapy

1 Feb 2019 to 31 Jul 2021

Awarded
£648,699
Total cost £1,441,553

"50% of people are expected to get cancer at some point in their life. Even with new therapies, many patients will experience unwanted side effects from their treatment that may range from minor psychological issues through to life threatening infections. With cancer patients spending a significant amount of time outside of healthcare facilities, it becom...

2017 Study Lead participant

Early stage design: Self-management of anaemia

1 Sep 2017 to 31 May 2018

Awarded
£68,686
Total cost £98,123

Over 3 million people suffer from iron-deficiency anaemia (IDA), a condition that can cause exhaustion and impair cognitive function. In a collaborative project, Eva Diagnostics is working alongside NIHR Diagnostics Evidence Cooperative London and the Department of Primary Care and Public Health, Imperial College London to undertake an early-stage design-...

2017 Collaborative R&D Lead participant

Comprehensive blood counts in a handheld device: home monitoring in chemotherapy

1 Mar 2017 to 31 Mar 2019

Awarded
£573,663
Total cost £819,518

For many individuals with cancer, chemotherapy forms a key aspect of treatment. Across the various types of chemotherapy, the majority carry significant side effects that often include the reduction of blood cell counts. The lowering of blood cell counts exposes individuals to higher risk of adverse events such as infection. Low blood counts are also the ...

2015 Feasibility Studies Lead participant

Comprehensive blood counts in a handheld device

1 Oct 2015 to 30 Sep 2016

Awarded
£139,855
Total cost £199,793

Eva Diagnostics is a medical technology and design company that is developing handheld diagnostic systems for the haematology sector. Building upon our existing platform technology, we are exploring the feasibility of a handheld diagnostic system capable of performing haematocrit, haemoglobin, white blood cell count, and platelet count from a single drop ...

2015 GRD Proof of Concept Lead participant

Development of an anaemia diagnostic for the point

1 Jan 2015 to 30 Jun 2016

Awarded
£98,745
Total cost £164,575

Eva Diagnostics is a medical design and engineering company commercialising technologies to improve the lives of anaemia sufferers across the globe. We have recently designed a new analysis technology that will lead to a low cost handheld device capable of diagnosing both the presence and type of anaemia. This device shall uniquely provide enough informat...

Product types

Collaborative R&D Feasibility Studies GRD Proof of Concept Study